Less than a tenth of people who could benefit from weight-loss injections such as Wegovy are able to get them, states the global health agency as it releases its initial guidance on the medications.
Given in excess of 1,000,000,000 people worldwide now living with obesity, it is advocating for increased and just availability to GLP-1 medication.
Based on forecasts, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"Our new guidance recognises that obesity is a long-term condition that can be addressed with comprehensive and lifelong care," remarked the agency's head Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are significant hurdles to universal access to the treatments that can assist patients in reducing significant body mass, explains the organization.
Skinny Jab Supply Crisis
Despite the present most optimistic outlook, the supply of GLP-1 therapies might only reach approximately 100 million people – less than 10% of eligible patients, as stated by the health organization.
The recommendation urges governments and firms to widen access, via strategies like voluntary licensing.
Exclusive production rights on a key compound – the core ingredient of Novo Nordisk's Wegovy – is scheduled to end in a number of countries in 2026.
The Way Weight-Loss Drugs Function
The injections mimick a body's own hormone to slow digestion, reduce hunger and increase the sense of being full so individuals consume fewer calories.
People typically begin shedding pounds in the initial weeks of commencing the weekly injections.
Studies suggests users may see weight return after a year of discontinuing the treatment, because their usual appetite resume.
Being carrying excess weight raises your risk for developing health problems, such as type 2 diabetes, heart disease, stroke, and certain malignancies.
Excess weight impacts people in countries worldwide and was linked to 3.7 million fatalities worldwide in 2024, according to the health agency.
